spacer
home > ebr > summer 2014 > radiation response
PUBLICATIONS
European Biopharmaceutical Review

Radiation Response

EBR: What attracted you to the pharmaceutical industry?

Adrian Treverton: I have worked in many markets over the years. In the radiation oncology field, there are really big advances being made by combining radiation with molecular targets. The idea that researchers can use the systems we build to ultimately improve the lives of cancer patients is hugely rewarding.

How has the industry changed since you entered it?

From a preclinical radiation oncology research perspective, the industry has really started to change its thinking. Radiation and chemotherapy used to be two separate treatment modalities, and radiation was seen as a palliative treatment. Now the pharma industry is looking at radiation as an essential tool in the spectrum of cancer care. This is being shown in new publications that combine radiation with chemotherapy and immunotherapies.

What big trends will we see developing over the next few years?

Researchers will further the use of radiation and molecular targets to treat cancer. Preclinically, we are already using human-derived cancer models along with radiation delivery to get a better understanding of treatment response at a genetic level. Future generations will see cancer therapies based on the patient’s genome, be it radiation, chemotherapy, or a combination of both.

What should the industry focus on in 2014-15?

The industry should recognise that 60-70% of cancer patients will receive radiation as part of their disease management. Developing agents that complement radiation delivery will lead to great success in patient outcomes. In addition, radiation can be helpful in many other indications, which can be enhanced with the right molecular targets.

What are your goals for the coming year?

My company’s vision is a future where every patient receives patient-centred healthcare. We are enabling researchers to advance translational medicine by providing clinically relevant technology. My goal is to continue to promote the use of radiation in cancer research, and continue to develop our technology in line with the needs of our researchers.

What inspires you in your daily life?

I have lost close family and friends to cancer, so I am inspired by the fact that I can contribute to the fight against this disease.

What is the secret to your success?

My customers are at the top of my organisation; I listen to them and give the best support and service. You cannot enhance technology without hearing what your customers are saying.

How do you think the pharma industry as a whole will change over the next decade?

I would like to see radiation therapy being utilised in the most effective way to enhance patient care, for many different indications beyond cancer. A key to this is the pharma industry developing drugs that complement and enhance the effects of radiation.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Adrian Treverton, Chief Operating Officer at Xstrahl Life Sciences, holds a Physics degree and MSc in Optics from Imperial College London. He joined Xstrahl in 2006 as Sales Director, leading the sales and marketing of its Orthovoltage X-ray therapy systems. In 2009, Adrian was instrumental in commercialising the SARRP from Johns Hopkins University.
spacer
Adrian Treverton
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Introducing Signant Health [Formerly CRF Bracket] and the Industry’s Most Comprehensive Patient-Centric Suite for Clinical Research

Philadelphia and London – June 10, 2019: CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, today launched as Signant Health (signanthealth.com). Uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite, Signant makes it easier to participate in – and sites and study teams to run – clinical trials. This intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable sponsors and CROs to extend the reach of drug development, expand patient opportunities and improve data quality.
More info >>

White Papers

Pharmacovigilance and Risk Management Information in Centralised Applications in the EU

United BioSource Corporation (UBC)

Getting a new medication approved for the EU market through the centralised procedure can be complex and needs expertise. The new EU pharmacovigilance legislation (Good Vigilance Practice, GVP) is now in effect and applicants need to be fully compliant. It is critical to have a thorough understanding of the regulatory process and requirements, and the expectations with regards to the pharmacovigilance system and the risk management plan. Ensuring consistency and an appropriate level of detail in the documentation submitted as part of the approval process will help prevent unnecessary delays.
More info >>

 
Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement